Loading
Acrivon Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$81.4M
No insider purchase over the last 90 days. The latest was filed 16 Jan 2026.
Acrivon Therapeutics, Inc.: what insiders have been doing
Acrivon Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 32 filings signed by 8 insiders.
Open-market activity splits into 3 purchases totalling €98k and 10 sales totalling €35k; 3 insiders sit on the buying side and 6 insiders on the selling side. Netting one side against the other leaves €63k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €71k, bought by Blume-Jensen Peter and made public on 16 January 2026. Those buying include 1 finance chief, 1 senior executive and 1 chief executive.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (16 January 2026) now reads 275 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 32 filings, this issuer sits above that mark. Our records for Acrivon Therapeutics, Inc. go back to 2022, with 5 purchases and 17 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -77.9 m USD.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
119
Thresholds
n/a
Buy Volume
€24M
5 ops. · all time
Sell Volume
€3M
17 ops. · all time
Who traded when
BuySalePerceptive Advisors LLC4 sales
Peter Blume-Jensen1 buy3 sales
Mary Miller3 sales
Adam D. Levy1 buy1 sale
Eric Devroe1 buy1 sale
Erick Gamelin1 sale
+1 other insider
Since the insiders bought
- -9.2%Entry US$1.96 · Close at T+90 US$1.78
- -9.2%Entry US$1.96 · Close at T+90 US$1.78
- -15.7%Entry US$1.98 · Close at T+90 US$1.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.90
Analyst consensus
6 analysts1.43/5
US$7.00Target US$11.50(+505%)US$19.00
Income statement
EBITDA-US$82.8M
Net income-US$77.9M0.0% margin
Valuation
PER (forward)-1.2x
P/Book0.9x
Beta1.93
Balance sheet & cash
Market capUS$81.4M
Total debtUS$2.7M
Free Cash Flow-US$65.3M
Debt / Equity2%
Profitability & ownership
ROE-64.6%
ROA-38.0%
% insiders15.4%
% institutions50.3%
Last declaration on 7 October 2026
Declarations119 total
294 shares@ US$1.990.0007% mcap1.0% of flowCommon StockSEC:0000905148-26-004399:0
14,036 shares@ US$2.20640.033% mcap0.6% of flowCommon StockSEC:0000905148-26-003968:0
14,036 shares@ US$2.180.033% mcap100.0% of flowCommon StockSEC144:0000905148-26-003924
604 shares@ US$2.010.0013% mcap1.5% of flowCommon StockSEC:0000905148-26-003837:0
1,229 shares@ US$2.010.0027% mcap0.1% of flowCommon StockSEC:0000905148-26-003836:0
484 shares@ US$2.010.0011% mcap0.0% of flowCommon StockSEC:0000905148-26-003836:1
400 shares@ US$2.010.0009% mcap3.1% of flowCommon StockSEC:0000905148-26-003838:0
185 shares@ US$2.010.0004% mcap0.6% of flowCommon StockSEC:0000905148-26-003839:0
101 shares@ US$2.010.0002% mcap5.0% of flowCommon StockSEC:0000905148-26-003840:0
1,142 shares@ US$1.570.0020% mcap9.9% of flowCommon StockSEC:0000905148-26-003499:0
573 shares@ US$1.760.0011% mcap1.8% of flowCommon StockSEC:0000905148-26-003334:0
13,729 shares@ US$1.790.5% of flowCommon StockSEC:0000905148-26-002652:0
3,888,888 shares@ US$1.806.82% mcap17.6% of flowCommon StockSEC:0001231919-26-000396:0
558 shares@ US$1.781.7% of flowCommon StockSEC:0000905148-26-001768:0
14,265 shares@ US$1.530.4% of flowCommon StockSEC:0000905148-26-001010:0
116 shares@ US$1.634.6% of flowCommon StockSEC:0000905148-26-000939:0
217 shares@ US$1.630.6% of flowCommon StockSEC:0000905148-26-000937:0
471 shares@ US$1.632.9% of flowCommon StockSEC:0000905148-26-000936:0
723 shares@ US$1.631.4% of flowCommon StockSEC:0000905148-26-000935:0
1,302 shares@ US$1.630.0% of flowCommon StockSEC:0000905148-26-000934:0
659 shares@ US$1.982.3% of flowCommon StockSEC:0000905148-26-000281:0
8,832 shares@ US$1.698381.9% of flowCommon StockSEC:0000905148-26-000225:0
Canonical exit: 14 Apr 2026 (T+90)
49,000 shares@ US$1.6761.7% of flowCommon StockSEC:0000905148-26-000226:0
Canonical exit: 14 Apr 2026 (T+90)
10,000 shares@ US$1.721821.5% of flowCommon StockSEC:0000905148-26-000212:0
Canonical exit: 13 Apr 2026 (T+90)
19,904 shares@ US$2.300.9% of flowCommon StockSEC:0000905148-25-004179:0
25 of 119 declarations
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It utilizes a biomarker platform to identify patients who are likely to benefit from its treatments.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
